1118567-48-8
Chemical Structure
Bexagliflozin diproline
Synonym(s): EGT1442 diproline; EGT0001442 diproline; THR-1442 diproline
- CAS No.: 1118567-48-8
- Formula:C34H47ClN2O11
- Molecular Weight:695.20
IUPAC Name: L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (1:1)
InChIKey: DAQOCDWUCJBXEI-GUJHQGHLSA-N
SMILES: OC([C@@H]1CCCN1)=O.O[C@H]2[C@@H](O[C@@H]([C@H]([C@@H]2O)O)CO)C3=CC(CC4=CC=C(C=C4)OCCOC5CC5)=C(C=C3)Cl.OC([C@@H]6CCCN6)=O
Biological Activity: Bexagliflozin diproline (EGT1442 diproline; EGT0001442 diproline; THR-1442 diproline) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin diproline selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin diproline induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin diproline reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin diproline can be used for the research of type 2 diabetes mellitus, hypertensive stroke[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bexagliflozin diproline | Bexagliflozin diproline (EGT1442 diproline; EGT0001442 diproline; THR-1442 diproline) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin diproline selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin diproline induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin diproline reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin diproline can be used for the research of type 2 diabetes mellitus, hypertensive stroke. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
